品牌和更高成本的仿制药驱动可避免的医疗保险D部分支出:使用ACEis和ARB作为模型的定量分析
Ji Mei May Wong1, James A Reiffel2, Peter R Kowey3
1Department of Internal Medicine at Lankenau Medical Center, Wynnewood, PA, USA.
The American journal of medicine
|July 31, 2025
概括
医疗保险D部分可以通过转向仿制药节省数十亿美元. 将所有处方转换为成本最低的仿制药可以节省266亿美元.
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 医疗保险D部分为超过5000万受益人提供处方药保险.
- 与财政可持续性平衡药物覆盖是医疗保险D部分的一个关键挑战.
- ангиотензин转化酶抑制剂 (ACEis) 和 ангиотензинII受体阻断剂 (ARBs) 是广泛处方的药物.
研究的目的:
- 评估医疗保险D部分内ACEis和ARB的使用和支出趋势.
- 通过这些药物类别的通用替代策略来建模潜在的成本节约.
主要方法:
- 医疗保险D部分数据库 (2018-2022) 的回顾性分析.
- 检查了ACEis和ARB的处方药支出数据.
- 从两个替代场景中建模节省:品牌到通用和最低成本的通用.
主要成果:
- 从2018年到2022年,D部分的入学人数增加了13.7%.
- 尽管使用率增加,但ACEis和ARB的支出略有增长 (+2.30%).
- 仿制药的成本显著下降 (ACEis: -26.4%;ARBs: -13.3%).
- 估计潜在的节省额为4.29亿美元 (完全的仿制药替代) 和266亿美元 (最低成本的仿制药默认).
结论:
- 在医疗保险D部分,通过仿制药替代可实现显著的成本节约.
- 强制使用最便宜的通用配方提供了巨大的财政效益.
- 类似的节省成本的机会可能存在于其他常见的处方药类别.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
888
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
888
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
927
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
927
01:25Antihypertensive Drugs: Direct Renin Inhibitors
827
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
827
01:22Dose-Response Relationship: Potency and Efficacy
5.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.2K
01:17Drug Nomenclature
2.3K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
2.3K